European Organisation for Research and Treatment of Cancer - EORTC: all 352 studies

Page 1 of 4. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• Eortc MoBilE Device (EMBED)Not yet recruitingNCT07711080
• FLT3-ITD Targeted Therapy in Fit AML PatientsNot yet recruitingNCT07425808Phase 2/3
• Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsNot yet recruitingNCT07234877Phase 2
• Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 StudyRecruitingNCT06990061Not applicable
• Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative TreatmentNot yet recruitingNCT06978062Phase 1
• Vorasidenib Maintenance for IDH Mutant AstrocytomaRecruitingNCT06809322Phase 3
• Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingNCT06783348Phase 2
• OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)RecruitingNCT06462963Not applicable
• Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast CancerNot yet recruitingNCT06407401Phase 3
• 177Lu-DOTATATE for Recurrent MeningiomaRecruitingNCT06326190Phase 2
• Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder CancerNot yet recruitingNCT06310369Phase 2
• Adjuvant Tebentafusp in High Risk Ocular MelanomaRecruitingNCT06246149Phase 3
• Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsRecruitingNCT05974774Phase 3
• Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III StudyRecruitingNCT05904119Phase 3
• Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck CancerRecruitingNCT05815927Phase 3
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingNCT05512364Phase 3
• Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO ClassificationRecruitingNCT05259605
• PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)RecruitingNCT04790253Not applicable
• Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)RecruitingNCT04498767Not applicable
• Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaRecruitingNCT04128072Phase 2
• Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaRecruitingNCT04031677Phase 3
• E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for EuropeRecruitingNCT03818503
• SPECTA: Screening Cancer Patients for Efficient Clinical Trial AccessRecruitingNCT02834884
• Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyActive, not recruitingNCT03517137Phase 2Results posted
• A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaCompletedNCT03345095Phase 3Results posted
• Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.CompletedNCT03224104Phase 1Results posted
• Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedNCT02856893Phase 2Results posted
• Trabectedin for Recurrent Grade II/III MeningiomaCompletedNCT02234050Phase 2Results posted
• Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal SarcomaCompletedNCT01344018Not applicableResults posted
• Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)Active, not recruitingNCT00626990Phase 3Results posted
• Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare StudyWithdrawnNCT06347185Not applicable
• Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT06219317Phase 2
• Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT05724602Phase 2
• Chemo-free BRCA-targeted Neoadjuvant StrategyWithdrawnNCT05209529Phase 2
• Dissecting the Pathways of Therapy Resistance in Early Breast CancerTerminatedNCT04995575
• Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth GlioblastomaWithdrawnNCT04933942Phase 2
• Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract CancerWithdrawnNCT04796454Phase 2
• A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue SarcomaTerminatedNCT04780464Phase 3
• Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed MedulloblastomaTerminatedNCT04402073Phase 2
• REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)TerminatedNCT04218825Phase 2
• Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC PatientsActive, not recruitingNCT04127110Phase 2
• Long-term Surival of GIST Patients ≥ 10 Years on ImatinibWithdrawnNCT04097093
• Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnNCT04065165Phase 3
• Follow-up in Early and Locally Advanced Breast Cancer PatientsCompletedNCT03859453
• Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnNCT03818997Phase 2
• Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in GlioblastomaCompletedNCT03770468
• Trial in Low Grade Glioma Patients: Wait or TreatTerminatedNCT03763422Phase 3
• Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCCWithdrawnNCT03673735Phase 3
• Reduced Dose-density of Denosumab for Unresectable GCTBTerminatedNCT03620149Phase 2
• Adjuvant Palbociclib in Elderly Patients With Breast CancerActive, not recruitingNCT03609047Phase 2
• Study of Photopheresis in the Treatment of Erythrodermic MF and SSWithdrawnNCT03563040Phase 2
• Follow-up in Gynecological Cancer SurvivorsActive, not recruitingNCT03515993
• Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate CancerWithdrawnNCT03488810Phase 3
• Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2
• Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerTerminatedNCT03437200Phase 2
• PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2
• Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)WithdrawnNCT03319316Phase 2
• Imaging Biomarker in Cancer Drug Induced ILDStatus unknownNCT03294746Not applicable
• Pembrolizumab in Biliary Tract CancerCompletedNCT03260712Phase 2
• Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibActive, not recruitingNCT03235245Phase 2
• Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Active, not recruitingNCT03134118Phase 2
• Synergism of Immunomodulation and Tumor AblationCompletedNCT03101475Phase 2
• Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
• Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2
• Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal CarcinomaActive, not recruitingNCT02984410Not applicable
• ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate CancerActive, not recruitingNCT02972060Phase 2
• Trabectedin Maintenance Post 1st-line in STSTerminatedNCT02929394Phase 3
• Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaTerminatedNCT02863055Phase 2
• Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)WithdrawnNCT02856867Phase 2
• Ph II Nintedanib vs. Ifosfamide in Soft Tissue SarcomaTerminatedNCT02808247Phase 2
• Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerActive, not recruitingNCT02799706Phase 3
• Diffusion-Weighted MRI for Liver MetastasisCompletedNCT02781935
• Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerCompletedNCT02659384Phase 2
• Pembrolizumab in Untreated Extensive SCLCCompletedNCT02580994Phase 2
• SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial AccessWithdrawnNCT02507947
• A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical CancerWithdrawnNCT02501278Phase 2
• Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.SuspendedNCT02470065Phase 2
• Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPMStatus unknownNCT02436733Phase 2
• Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal CancerStatus unknownNCT02355353Not applicable
• SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial AccessWithdrawnNCT02307604
• Randomized Boost Versus no Boost Irradiation of Early Breast CancerCompletedNCT02295033Phase 3
• Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative ChemoStatus unknownNCT02273271Not applicable
• A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance ProgramCompletedNCT02218801
• Ph II CABOGIST in GISTCompletedNCT02216578Phase 2
• SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial AccessCompletedNCT02214134
• Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02205047Phase 2
• Phase III Radium 223 mCRPC-PEACE IIIActive, not recruitingNCT02194842Phase 3
• "InDACtion" vs "3+7" Induction in AMLStatus unknownNCT02172872Phase 3
• IRCI Gynae Sarcomas, High Grade Uterine SarcomaCompletedNCT01979393Phase 2
• Androgen Deprivation Therapy in Advanced Salivary Gland CancerCompletedNCT01969578Phase 2
• Minimal SN Tumor BurdenActive, not recruitingNCT01942603
• Ph II Cabazitaxel DD LiposarcomaCompletedNCT01913652Phase 2
• Cancer in Nursing Home ResidentsCompletedNCT01910376
• AF CRT +/- Nimorazole in HNSCCStatus unknownNCT01880359Phase 3
• Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation StudyStatus unknownNCT01838577
• Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate CancerCompletedNCT01819285Phase 3
• LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLCStatus unknownNCT01795521Phase 2
• Nintedanib(BIBF1120) in Thyroid CancerCompletedNCT01788982Phase 2
• Screening Platform for Clinical Trials in Advanced Colorectal CancerCompletedNCT01723969
• TAK-700 in Castration Resistant Prostate CancerWithdrawnNCT01658527Phase 2

← European Organisation for Research and Treatment of Cancer - EORTC overview and focus areas